ERLIN1

Erlin-1 · O75477 · ERLIN1 on Sugi Atlas →

0 patent compounds predicted against ERLIN1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ERLIN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin PHASE2/PHASE3UNKNOWN
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops PHASE2UNKNOWN
Investigator-initiated Clinical Trial of MIKE-1 PHASE1/PHASE2UNKNOWN
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer PHASE2COMPLETED
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer PHASE2WITHDRAWN
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC PHASE2COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Tamoxifen in Patients With Oesophageal Cancer PHASE1UNKNOWN
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Tracking Neurodegeneration in Early Wolfram Syndrome nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Consequences of Mutations in the SPG7 Gene at the Heterozygous State nanCOMPLETED
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans nanUNKNOWN
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Genetic Variation in CLTCL1 and Whole-body Glucose Control nanCOMPLETED
Phenotypic and Genotypic Characterization of Subjects With Syndromic Obesity: Identifying New Candidate Genes by Exome Sequencing (OBEXOME) nanCOMPLETED
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation? nanUNKNOWN
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders nanUNKNOWN
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ERLIN1 binder may also engage these)

ProteinNameSimilarity
Q5RCJ9 1.000 Q5RCJ9 →
Q91X78 1.000 Q91X78 →
Q58EG2 0.993 Q58EG2 →
Q28J34 0.992 Q28J34 →
Q5R7C5 0.991 Q5R7C5 →
Q6DKC0 0.989 Q6DKC0 →
Q5XH03 0.989 Q5XH03 →
Q28DX1 0.988 Q28DX1 →
Q8BFZ9 0.986 Q8BFZ9 →
A3QK16 0.985 A3QK16 →
ERLIN2 Erlin-2 0.985 landscape →
B5DEH2 0.985 B5DEH2 →
Q1RMU4 0.981 Q1RMU4 →
PHB1 Prohibitin 1 0.957 landscape →
P84173 0.955 P84173 →
P67779 0.953 P67779 →
P67778 0.953 P67778 →
Q3T165 0.951 Q3T165 →
P24156 0.933 P24156 →
B9N1F9 0.932 B9N1F9 →
Q9MB46 0.931 Q9MB46 →
Q9SWE7 0.930 Q9SWE7 →
Q5FVD6 0.930 Q5FVD6 →
E0CSI1 0.930 E0CSI1 →
P11497 0.929 P11497 →
Q3B8M3 0.928 Q3B8M3 →
Q5SWU9 0.927 Q5SWU9 →
Q01587 0.927 Q01587 →
Q6GQI7 0.927 Q6GQI7 →
Q32PW3 0.927 Q32PW3 →